Compare · DXCM vs SNWV
DXCM vs SNWV
Side-by-side comparison of DexCom Inc. (DXCM) and SANUWAVE Health Inc. (SNWV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SNWV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 236.3x SNWV ($125.1M).
- Over the past year, DXCM is down 10.6% and SNWV is down 50.0% - DXCM leads by 39.4 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 1 for SNWV).
- DXCM has more recent analyst coverage (25 ratings vs 2 for SNWV).
- Company
- DexCom Inc.
- SANUWAVE Health Inc.
- Price
- $76.59+5.15%
- $14.58-1.69%
- Market cap
- $29.57B
- $125.1M
- 1M return
- +25.71%
- -11.56%
- 1Y return
- -10.56%
- -50.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 1
- Recent ratings
- 25
- 2
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest SNWV
- SEC Form SD filed by SANUWAVE Health Inc.
- Sanuwave Announces Revenues and Financial Results for Q1 FY2026
- SANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by SANUWAVE Health Inc.
- Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
- Large owner Opaleye Management Inc. sold $574,240 worth of shares (35,581 units at $16.14) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by SANUWAVE Health Inc.
- Large owner Opaleye Management Inc. sold $1,274,971 worth of shares (70,648 units at $18.05) (SEC Form 4)
- SEC Form DEFA14A filed by SANUWAVE Health Inc.
- SEC Form DEF 14A filed by SANUWAVE Health Inc.